Authors:
WEISBURG JH
CURCIO M
CARON PC
RAGHU G
MECHETNER EB
ROEPE PD
SCHEINBERG DA
Citation: Jh. Weisburg et al., THE MULTIDRUG-RESISTANCE PHENOTYPE CONFERS IMMUNOLOGICAL RESISTANCE, The Journal of experimental medicine, 183(6), 1996, pp. 2699-2704
Citation: Pc. Caron et al., INTERLEUKIN-2 ENHANCEMENT OF CYTOTOXICITY BY HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) IN MYELOGENOUS LEUKEMIA, Clinical cancer research, 1(1), 1995, pp. 63-70
Authors:
CARON PC
LAI LT
MASLAK P
NIKULA T
JURCIC J
SCHEINBERG DA
Citation: Pc. Caron et al., INDUCTION OF APOPTOSIS OF HL-60 CELLS USING THE SHORT-RANGED ALPHA-PARTICLE EMITTING 213-BISMUTH CONJUGATED TO HUMANIZED ANTI-CD33 M195 - PROSPECTS FOR SELECTIVE SINGLE-CELL KILLING IN MYELOID-LEUKEMIA, Blood, 86(10), 1995, pp. 2998-2998
Authors:
CARON PC
SCHWARTZ MA
CO MS
QUEEN C
FINN RD
GRAHAM MC
DIVGI CR
LARSON SM
SCHEINBERG DA
Citation: Pc. Caron et al., MURINE AND HUMANIZED CONSTRUCTS OF MONOCLONAL-ANTIBODY M195 (ANTI-CD33) FOR THE THERAPY OF ACUTE MYELOGENOUS LEUKEMIA, Cancer, 73(3), 1994, pp. 1049-1056
Authors:
CARON PC
JURCIC JG
SCOTT AM
FINN RD
DIVGI CR
GRAHAM MC
JUREIDINI IM
SGOUROS G
TYSON D
OLD LJ
LARSON SM
SCHEINBERG DA
Citation: Pc. Caron et al., A PHASE-1B TRIAL OF HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) INMYELOID-LEUKEMIA - SPECIFIC TARGETING WITHOUT IMMUNOGENICITY, Blood, 83(7), 1994, pp. 1760-1768
Authors:
CO MS
SCHEINBERG DA
AVDALOVIC NM
MCGRAW K
VASQUEZ M
CARON PC
QUEEN C
Citation: Ms. Co et al., GENETICALLY-ENGINEERED DEGLYCOSYLATION OF THE VARIABLE DOMAIN INCREASES THE AFFINITY OF AN ANTI-CD33 MONOCLONAL-ANTIBODY, Molecular immunology, 30(15), 1993, pp. 1361
Authors:
SGOUROS G
GRAHAM MC
SCOTT A
CARON PC
DIVGI CR
FINN R
CARABASI M
LARSON SM
SCHEINBERG DA
Citation: G. Sgouros et al., CLINICAL IMPLEMENTATION OF MODELING-BASED RADIOIMMUNOTHERAPY TREATMENT PLANNING - I-131 M195 ANTIBODY AGAINST CHRONIC MYELOGENOUS LEUKEMIA, The Journal of nuclear medicine, 34(5), 1993, pp. 105-105
Authors:
JURCIC JG
CARON PC
MILLER WH
YAO TJ
MASLAK P
FINN R
LARSON SM
WARRELL RP
SCHEINBERG DA
Citation: Jg. Jurcic et al., I-131-LABELED ANTI-CD33 (I-131-M195) MAY PROLONG DISEASE-FREE SURVIVAL (DFS) IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) AFTER REMISSIONINDUCTION WITH ALL-TRANS-RETINOIC ACID (RA), Blood, 82(10), 1993, pp. 10000193-10000193
Authors:
CARON PC
JURCIC JG
SCOTT AM
FINN RD
DIVGI CR
GRAHAM MC
JUREIDINI IM
SGOUROS G
TYSON D
OLD LJ
LARSON SM
SCHEINBERG DA
Citation: Pc. Caron et al., A PHASE-1B TRIAL OF HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) INMYELOID-LEUKEMIA - SPECIFIC TARGETING WITHOUT IMMUNOGENICITY, Blood, 82(10), 1993, pp. 10000329-10000329